Document is current

Article History

Received: 24 December 2024

Accepted: 24 March 2025

First Online: 12 April 2025

Declarations

:

: B.E.W., R.A.S., A.C.H., and C.M.M. report no conflicts of interest. M.M.S. has acted as a consultant for Novo Nordisk. D.H.vR. has acted as a consultant for and received honoraria from Boehringer Ingelheim-Eli Lilly Alliance, Merck, Sanofi, and AstraZeneca, and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Merck. All honoraria are paid to the employer Amsterdam University Medical Center. HJLH reports funding to conduct clinical trials from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and Novo Nordisk (all to the University of Groningen); consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, DImerix, Eli Lilly, Fresenius, Gilead, Janssen, Novo Nordisk, Novartis, and Travere Therapeutics; payment of honoraria for lectures from AstraZeneca, Novo Nordisk, and Bayer; support for traveling to and attending the American Diabetes Association meeting and American Society of Nephrology meeting from AstraZeneca and Eli Lilly (to HJLH and the University of Groningen); and receipt of the study drug from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and Novo Nordisk.

: The RECOLAR study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the VU University Medical Center (RECOLAR: protocol code DC2019RECOLAR01, date of approval 16 September, 2020).

: The study was registered at ClincialTrials.gov (ID: NCT04238702). The local authorities and medical ethical review board of the VU University Medical Center (Amsterdam, The Netherlands METc no. NL71049.029.19) approved all protocol-specific documents, and all study procedures were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

: Informed consent was obtained from all subjects involved in the study.